Overview
TB-500 is a synthetic peptide corresponding to a region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein present in virtually all human and animal cells. Tβ4 is one of the most abundant and ubiquitous intracellular peptides in the body, where it serves as the main actin-sequestering molecule. TB-500 encompasses the actin-binding domain of Tβ4 and is believed to retain much of its biological activity. Research in animal models has shown Tβ4 to be involved in wound healing, inflammation regulation, angiogenesis, and cardiac tissue protection. It has been studied in a Phase II clinical trial for venous stasis ulcers, making it one of the few peptides in this category with any human clinical data.
Mechanism
TB-500's mechanism centers on its ability to bind G-actin (monomeric actin) and promote cell migration through upregulation of the MRTF/SRF transcriptional pathway. By sequestering actin, it modulates the cytoskeleton and facilitates the migration of endothelial cells and keratinocytes to wound sites. It also appears to promote angiogenesis, reduce inflammation via downregulation of inflammatory cytokines, and activate stem cell recruitment.
Research Areas
Side Effects (Preclinical)
- – Transient fatigue in some animal subjects
- – Mild injection-site reactions
- – No significant adverse effects reported in Phase II clinical trial for venous ulcers
Cautions
- – For research use only — not approved for human consumption
- – No long-term human safety data
- – May theoretically influence tumor angiogenesis; researchers note this as an area for further study
What the research shows
TB-500 is often studied alongside BPC-157 due to overlapping research areas in tissue repair, though their mechanisms are distinct. BPC-157 primarily acts via the nitric oxide system and angiogenesis, while TB-500 centers on actin dynamics and cell migration. They are frequently combined in research stacks for this reason.
The venous stasis ulcer clinical trial (Guarnera et al., 2008) represents one of the more rigorous human data points in this peptide category — participants receiving Tβ4 showed significantly accelerated wound closure versus placebo.
References
- Thymosin beta4 accelerates wound healing — Malinda KM et al. (1999)
- Phase II randomized, double-blind, placebo-controlled study of thymosin beta4 for venous leg ulcers — Guarnera G et al. (2008)